mAb therapy controls CNS-resident lyssavirus infection via a CD4 T cell-dependent mechanism.
Mastraccio KE, Huaman C, Coggins SA, Clouse C, Rader M, Yan L, Mandal P, Hussain I, Ahmed AE, Ho T, Feasley A, Vu BK, Smith IL, Markotter W, Weir DL, Laing ED, Broder CC, Schaefer BC.
Mastraccio KE, et al. Among authors: markotter w.
EMBO Mol Med. 2023 Oct 11;15(10):e16394. doi: 10.15252/emmm.202216394. Epub 2023 Sep 28.
EMBO Mol Med. 2023.
PMID: 37767784
Free PMC article.